StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Friday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 3.0 %

Shares of BTX stock opened at $0.45 on Friday. The firm has a market capitalization of $26.41 million, a P/E ratio of -0.20 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The firm’s fifty day simple moving average is $0.45 and its 200 day simple moving average is $1.12.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.